OncoMatch/Clinical Trials/NCT05645718
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Is NCT05645718 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for leukemia.
Treatment: Cyclophosphamide · Vincristine · Blinatumomab · Methotrexate · Cytarabine · Mercaptopurine · Prednisone · Pegfilgrastim · Inotuzumab ozogamicin · Rituximab · Dexamethasone — To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Biomarker criteria
Required: CD19 expression (≥ 5% blasts)
Required: CD22 expression (≥ 5% blasts)
Allowed: CD20 expression
Demographics
Lab requirements
Kidney function
Estimated GFR ≥ 60 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination
Liver function
Total serum bilirubin ≤1.5x ULN (≤3x ULN if Gilbert's syndrome); ALT/AST ≤3x ULN (≤5x ULN if suspected leukemic liver involvement)
Cardiac function
Left ventricular ejection fraction (EF) < 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received >450mg/m2 of doxorubicin and cannot receive anthracyclines
Total serum bilirubin ≤1.5x ULN. Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN. ALT/AST ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement. Estimated GFR ≥ 60 mL/min/1.73 m2. Left ventricular ejection fraction (EF) < 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received >450mg/m2 of doxorubicin and cannot receive anthracyclines.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05645718 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify